New Risk • Jun 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 42% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£17m net loss next year). Share price has been volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$5m (UK£1.7m revenue, or US$2.2m). Tillkännagivande • Jun 15
4basebio PLC Appoints Jeff Coller to Strategic Advisory Board 4basebio PLC announced the appointment of Jeff Coller, Ph.D., to its Strategic Advisory Board. Jeff Coller, Ph.D., is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at The Johns Hopkins University and the Inaugural Director of the RNA Innovation Center. With over 30 years dedicated to the study of mRNA, his pioneering research has fundamentally shifted the scientific understanding of gene expression, demonstrating that the genetic code acts as a master determinant of mRNA stability and transcript fate. Dr. Coller’s transformative work has not only shaped foundational RNA biology but has also accelerated the development of life-saving mRNA therapeutics and vaccines. He is the co-founder of Tevard Biosciences, a founding member and Board Director of the Alliance for mRNA Medicines, and an elected Fellow of the American Association for the Advancement of Science (AAAS). He earned his Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and completed his postdoctoral fellowship at the Howard Hughes Medical Institute. Tillkännagivande • May 22
4Basebio plc Provides Earnings Guidance for the Year 2026 4basebio PLC provided earnings guidance for the year 2026. For the year, the Group expects continued strong revenue growth and expects to remain loss-making. Tillkännagivande • May 21
4basebio PLC, Annual General Meeting, Jun 30, 2026 4basebio PLC, Annual General Meeting, Jun 30, 2026. Location: the offices of 4basebio plc, United Kingdom Reported Earnings • May 21
Full year 2025 earnings released: UK£1.09 loss per share (vs UK£0.94 loss in FY 2024) Full year 2025 results: UK£1.09 loss per share (further deteriorated from UK£0.94 loss in FY 2024). Net loss: UK£16.9m (loss widened 37% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Tillkännagivande • May 12
4basebio PLC Launches Enzymatic ssDNA Platform 4basebio PLC announced the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines. Built on a proprietary enzymatic manufacturing process, the platform provides biopharma with high-purity, long-form ends protected ssDNA templates, designed to overcome critical manufacturing and performance bottlenecks associated with traditional chemical synthesis in CRISPR-based gene editing, enabling large-scale, clinically viable therapeutics. With the growth of gene editing and with a particular need for complex "knock-in" applications, the demand for longer, purer and safer DNA templates has increased exponentially. 4basebio’s ssDNA offering enables the production of constructs up to 10,000 nucleotides with protected ends, ensuring stability, reduced immunogenicity and a cleaner path to clinical manufacturing. The technical advantages of the platform will be showcased at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston, MA. Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, will deliver a presentation titled "An enzymatic ssDNA platform addresses manufacturing and performance bottlenecks in non-viral CRISPR gene editing" on 14 May at 9:00 AM EDT. At ASGCT, I look forward to presenting data that demonstrates how our long-form ssDNA constructs significantly enhance Homology Directed Repair (HDR) gene editing efficiency while maintaining superior cell viability in sensitive primary cell types. This technology is the bridge between discovery-phase editing and large-scale clinical success. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. New Risk • Apr 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). New Risk • Mar 24
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €85.5m (US$99.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 45% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£1.8m revenue, or US$2.4m). Market cap is less than US$100m (€85.5m market cap, or US$99.0m). Tillkännagivande • Mar 03
4basebio PLC Promotes Christine Wolosin to Chief Commercial Officer 4basebio PLC announced the promotion of Christine Wolosin to Chief Commercial Officer. Christine, who joined 4basebio in September 2025 as Vice President, Business Development, will lead the Company's global commercial strategy, business development initiatives, and customer engagement as the Company scales its innovative synthetic DNA platform to serve the rapidly growing cell and gene therapy, mRNA, and vaccine markets.Christine’s promotion follows the appointment of Dr Amy Walker as Chief Executive Officer, replacing Dr Heikki Lanckriet. Christine will work closely with Amy to execute 4basebio’s accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers seek alternatives to plasmid DNA. Christine brings more than 25 years of experience in the life sciences industry, with a proven track record of building and scaling go-to-market capabilities in the cell and gene therapy space. Prior to joining 4basebio, she served as Vice President of Business Development at Emmes, where she led the buildout of the North America commercial organisation to support growth in biopharma innovator trials and later-phase studies. She established scalable, globally aligned commercial processes and advanced Emmes’ strategic positioning within the biopharma sector. Christine has also held senior global commercial leadership roles at leading life sciences organizations including TriLink BioTechnologies and Thermo Fisher Scientific, where she led the go-to-market launches for a number of advanced therapy offerings, including Thermo Fisher Scientific’s viral vector manufacturing expansion at its flagship Plainville, Massachusetts facility. Tillkännagivande • Feb 10
4basebio PLC Announces CEO Changes 4basebio PLC announced that Dr Amy Walker has been appointed as Chief Executive Officer, succeeding Dr Heikki Lanckriet, Founder of the Company. After six years in the role, Heikki has stepped down as CEO in order to lead a newly formed entity which will be focussed on advancing the Hermes nanoparticle platform into the clinic. The Board and Executive Leadership team determined that Amy, with her deep knowledge of the company and commercially-focussed skillset and experience, is the right candidate to succeed Heikki as the Company prepares for accelerated commercial growth. Heikki will remain on the Board and will also continue to support the Company’s scientific and technical leadership. David Roth will join Heikki in the newly formed entity and will step down as Chief Financial Officer and as a Director, following an orderly handover period. Amy has been with the Company for more than five years most recently serving as Chief Operating Officer. She has played a key role in scaling 4basebio’s GMP manufacturing capabilities, strengthening direct engagement with top-tier biopharma customers and supporting the Company’s growth operationally and strategically. As Chief Executive Officer, Amy will lead an accelerated commercial growth strategy, focusing on deepening penetration of the synthetic DNA market as customers increasingly seek alternatives to plasmid DNA, and building on the Company’s recent GMP milestone to support clinical programmes in cell and gene therapy and vaccine development. Since the Company’s formation in 2020, Heikki has been responsible for leading 4basebio as it scaled its synthetic DNA technology from concept to clinic, built a global customer base and stewarded 4basebio in building its high-quality investor base. Board Change • Jan 05
Less than half of directors are independent There are 9 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (7 non-independent directors). Chair of Strategic Advisory Board Deborah Barbara is the most experienced director on the board, commencing their role in 2024. Independent Non-executive Director Alan Malus was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Dec 08
Less than half of directors are independent There are 9 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (7 non-independent directors). Chair of Strategic Advisory Board Deborah Barbara is the most experienced director on the board, commencing their role in 2024. Independent Non-executive Director Alan Malus was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Oct 28
Less than half of directors are independent There are 9 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. 1 independent director (7 non-independent directors). Chair of Strategic Advisory Board Deborah Barbara is the most experienced director on the board, commencing their role in 2024. Independent Non-executive Director Alan Malus was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 01
First half 2025 earnings released: UK£0.50 loss per share (vs UK£0.45 loss in 1H 2024) First half 2025 results: UK£0.50 loss per share (further deteriorated from UK£0.45 loss in 1H 2024). Net loss: UK£7.80m (loss widened 36% from 1H 2024). Revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. New Risk • Jun 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 21% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 43% per year over the past 5 years. Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£18m net loss next year). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (UK£933k revenue, or US$1.3m). Reported Earnings • Jun 02
Full year 2024 earnings released: UK£0.94 loss per share (vs UK£0.62 loss in FY 2023) Full year 2024 results: UK£0.94 loss per share (further deteriorated from UK£0.62 loss in FY 2023). Net loss: UK£12.3m (loss widened 61% from FY 2023). Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings. New Risk • May 30
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 41% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.2m). Earnings are forecast to decline by an average of 41% per year for the foreseeable future. Revenue is less than US$1m (UK£596k revenue, or US$803k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£15m net loss next year). Tillkännagivande • May 28
4basebio PLC, Annual General Meeting, Jun 27, 2025 4basebio PLC, Annual General Meeting, Jun 27, 2025. New Risk • Apr 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-UK£5.2m). Revenue is less than US$1m (UK£596k revenue, or US$788k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (UK£12m net loss in 3 years). Tillkännagivande • Apr 02
4basebio Receives GMP Licence for its UK DNA Manufacturing Facility 4basebio PLC announced that it has received Good Manufacturing Practice (GMP) certification from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its UK DNA manufacturing facility. The GMP certification (MIA) granted by the MHRA authorises 4basebio to manufacture and supply both Investigational Medicinal Product (IMP) Drug Substance (Active Pharmaceutical Ingredient; API) and Critical Starting Biological Medicinal materials used in Advanced Therapy Medicinal Products (ATMPs) from its state-of-the-art manufacturing facility in Cambridge. The grant of the GMP certification marks a significant achievement for the Company, proving its ability to produce high-quality, advanced synthetic DNA that meets regulatory standards for clinical applications. The certification both strengthens the Company’s position in the field of advanced therapeutics and progresses the Company towards future product commercialisation and patient care for a range of advanced therapies. Tillkännagivande • Jan 08
4basebio PLC Appoints Gabe Longoria as Chief Commercial Officer 4basebio PLC announced the appointment of Mr. Gabe Longoria as Chief Commercial Officer (“CCO”) of the Company. The appointment follows the completion of the £40 million investment announced on 12 November 2024, which marked a key milestone in the Company’s journey to deliver scalable, high-quality synthetic DNA solutions to the global market, addressing critical needs in the gene therapy and mRNA vaccine sectors. Gabe’s expertise in scaling commercial operations will play a crucial role in ensuring the Company’s synthetic DNA products reach their full market potential and the Company is well-positioned to deliver on its growth and commercialisation goals in 2025 and beyond. Gabe joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations Ltd. (“Astrea”). During his leadership, the company achieved exceptional financial growth, doubling revenues over a three-year period and expanding its market share globally. His strategic approach to scaling operations and fostering key partnerships solidified Astrea’s position as a leader in biopharmaceutical manufacturing solutions. Gabe has over two decades of commercial leadership in the life sciences sector and expertise in driving revenue growth, market expansion, and strategic partnerships for companies. Tillkännagivande • Dec 17
4basebio PLC Announces Appointment of Alan Malus as Independent Non-Executive Director 4basebio PLC announced the appointment of Alan Malus as Independent Non-executive Director of the Company, as of 16 December 2024. Mr. Malus has over 18 years of experience in life sciences and diagnostics, having most recently served as Corporate Executive Vice President and President of the Laboratory Products and Services Segment at Thermo Fisher Scientific. He joined Thermo Fisher in 1998, holding numerous executive positions including President Analytical Technologies Group, President Lab Products Group, and President Customer Chanels Group. Prior to this, Mr. Malus spent nearly 15 years in the automotive industry, working with Ford, Chrysler, and Textron Inc., where he served as Vice President of Finance. Since 2023, Mr. Malus has been a Director at Industrial Physics Inc. He also serves as Director at Azenta Life Sciences. Previously, he served as a Director at PHC Holdings Corporation in Japan (2021 to 2022). Mr. Malus graduated from the University of Michigan in 1981, starting his career as a financial analyst at Ford in 1984 and moving to Chrysler in 1986. Current Directorships: USAJapan; Azenta Inc.; Industrial Physics Inc. Previous Directorships held in the past five years: PHC Holdings Corporation. Recent Insider Transactions • Dec 01
Key Executive recently bought €190k worth of stock On the 28th of November, Heikki Lanckriet bought around 12k shares on-market at roughly €15.80 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €1.5m. Heikki has been a buyer over the last 12 months, purchasing a net total of €190k worth in shares. Tillkännagivande • Nov 13
4basebio PLC has completed a Follow-on Equity Offering in the amount of £40.000005 million. 4basebio PLC has completed a Follow-on Equity Offering in the amount of £40.000005 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 2,666,667
Price\Range: £15
Transaction Features: Subsequent Direct Listing Reported Earnings • Oct 01
First half 2024 earnings released: UK£0.45 loss per share (vs UK£0.29 loss in 1H 2023) First half 2024 results: UK£0.45 loss per share (further deteriorated from UK£0.29 loss in 1H 2023). Net loss: UK£5.73m (loss widened 61% from 1H 2023). Tillkännagivande • Aug 09
4Basebio plc Announces Formation of Strategic Advisory Board and Board Appointment 4basebio PLC announced the formation of a Strategic Advisory Board and the appointment of Dr. Amy Walker, the Vice President of Research and Business Development to the Board of Directors of the Company as Chief Operating Officer. Strategic Advisory Board Effective from 1 July 2024, the Company formed a Strategic Advisory Board (“SAB”), with the purpose of offering the Company’s leadership team valuable advice and industry insight spanning technical, operational, commercial and strategic matters as well as supporting the Company in the realisation of its growth goals and objectives. The SAB advisers are engaged for an initial period of 12 months from its formation and will meet with the leadership team periodically. The SAB comprises the following experts: Bertrand Coissac, CEO at Twogene: Mr. Coissac has extensive experience in the life science industry with a focus on cell and gene therapy manufacturing. Before co-founding and leading Twogene, Mr. Coissac was Vice President of Corporate Development at Polyplus which was successfully acquired by Sartorius in July 2023. Lawrence Pitcher, VP at Catalent Pharma Solutions: Mr. Pitcher is currently the Vice President and General Manager, Maryland Gene Therapy Sites at Catalent Pharma Solutions. He brings significant operational and business experience from his current Catalent role and previous roles at Thermo Fisher Scientific where he was most recently the General Manager of the Advance Therapies business. Deborah Barbara, Former Vice President at Maravai Life Sciences: Ms. Barbara has over 30 years of life science industry experience in a variety of strategic business and corporate development roles, most recently as Vice President of Strategy and Corporate Development for Maravai Life Sciences. Prior to joining Maravai, Ms. Barbara was General Manager of Nucleic Acid Therapeutics business for Thermo Fisher Scientific. Appointment of Director: In addition to the above, the Company announces the appointment of Dr. Amy Walker as Chief Operating Officer of the Company. Dr. Walker joined 4basebio in November 2020 and has served as the Vice President of Research and Business Development at the Company. Dr. Walker has a background in molecular biology and gene editing technologies, along with associated nucleic acid nanoparticle delivery platforms. She holds a PhD from UCL Institute of Child Health and was awarded the prestigious Bogue Fellowship, conducting part of her doctoral studies at both University of British Colombia and McGill University, Montreal. Dr. Walker has many years scientific and commercial experience in life sciences, has published scientific papers and is named inventor on numerous multidisciplinary patents. She currently holds non-executive director Board positions on two other high growth healthcare companies. Tillkännagivande • Jun 30
4Basebio plc Announces Hansjörg Plaggemars, Non-Executive Director, Step Down from the Board 4basebio PLC announced that Hansjörg Plaggemars, a non-executive director, requested to step down from the board due to other business commitments which the board has accepted with immediate effect. The board would like to thank Mr. Plaggemars for his contribution to the Company. Tillkännagivande • Jun 08
4basebio PLC, Annual General Meeting, Jun 28, 2024 4basebio PLC, Annual General Meeting, Jun 28, 2024. Board Change • Jun 07
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.